Progression of Alzheimer's disease (AD) entails deterioration or aberrant function of multiple
brain cell types, eventually leading to neurodegeneration and cognitive decline. Defining …

Importance Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging.
Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)–positive patients …

Proteomics can shed light on the dynamic and multifaceted alterations in neurodegenerative
disorders like Alzheimer's disease (AD). Combining radioligands measuring β-amyloid (Aβ) …

Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid
biomarkers are highly needed. We employed proximity extension-based assays to measure …

Recent expansion of proteomic coverage opens unparalleled avenues to unveil new
biomarkers of Alzheimer's disease (AD). Among 6,361 cerebrospinal fluid (CSF) proteins …

The integration of quantitative trait loci (QTLs) with disease genome-wide association
studies (GWASs) has proven successful in prioritizing candidate genes at disease …

Alzheimer's disease (AD) is among the most common neurodegenerative disorders. AD is
characterized by deposition of neurofibrillary tangles and amyloid plaques, leading to …

Autosomal dominant Alzheimer's disease (ADAD) offers a unique opportunity to study
pathophysiological changes in a relatively young population with few comorbidities. A …

Background Loss of synaptic functionality has been recently identified as an early-stage
indicator of neurological diseases. Consequently, monitoring changes in synaptic protein …

Alzheimer's disease (AD) is currently defined by the aggregation of amyloid-β (Aβ) and tau
proteins in the brain. Although biofluid biomarkers are available to measure Aβ and tau …